SCHEMBL6766337

SCHEMBL6766337

Cc1cccc(C)c1NC(=O)CN1CCN(C(=O)C(O)Cc2ccccc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.52
CYP2D6 P10635 2/20 0.52
ADRB1 P08588 2/20 0.52
ADRA2A P08913 2/20 0.52
ADRA2B P18089 2/20 0.52
ADRA2C P18825 2/20 0.52
ADRA1A P35348 2/20 0.52
DRD3 P35462 2/20 0.52
HTR2B P41595 2/20 0.52
KCNH2 Q12809 2/20 0.52
TSHR P16473 1/20 0.52
NFKB1 P19838 1/20 0.52
ADRB2 P07550 1/20 0.52
SCN5A Q14524 1/20 0.52
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
LMNA P02545 3/20 0.51
NPSR1 Q6W5P4 2/20 0.51
MLNR O43193 1/20 0.51
NR1I2 O75469 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6763792 0.89 KMT2A (0.52) CYP3A4CYP2D6ADRB1ADRA2AADRA2B
SCHEMBL6766657 0.89 KMT2A (0.52) CYP3A4CYP2D6ADRB1ADRA2AADRA2B
SCHEMBL6286482 0.84 CYP3A4 (0.64) CYP3A4CYP2D6ADRB1ADRA2AADRA2B
SCHEMBL6769471 0.81 ALDH1A1 (0.59) CYP3A4CYP2D6ADRB1ADRA2AADRA2B
SCHEMBL6763867 0.81 TACR1 (0.49) CYP3A4CYP2D6ADRB1ADRA2AADRA2B
SCHEMBL6277857 0.81 MEN1 (0.65) TSHRMEN1KMT2ALMNANPSR1
SCHEMBL2327539 0.80 ALDH1A1 (0.64) CYP3A4CYP2D6ADRB1ADRA2AADRA2B
SCHEMBL6767027 0.80 TSHR (0.54) CYP3A4CYP2D6ADRB1ADRA2AADRA2B
SCHEMBL8556384 0.78 MEN1 (0.60) CYP3A4CYP2D6ADRB1ADRA2AADRA2B
SCHEMBL6283554 0.78 CYP3A4 (0.62) CYP3A4CYP2D6ADRB1ADRA2AADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010044541-A1 Substituted piperazine compounds GILEAD PALO ALTO, INC. 2001-11-22 US claimed
WO-2001062749-A1 SUBSTITUTED PIPERAZINE COMPOUNDS CV THERAPEUTICS, INC. (US) 2001-08-30 WO claimed
US-6677343-B2 USEFUL IN PROTECTING SKELETAL MUSCLES AGAINST DAMAGE RESULTING FROM TRAUMA OR TO PROTECT AGAINST LIMPING, TREATING SHOCK CONDITIONS, PRESERVE DONOR TISSUE AND ORGANS USED IN TRANSPLANTS, AND IN TREATING CARDIOVASCULAR DISEASES CV THERAPEUTICS, INC. 2004-01-13 US disclosed
US-20010044541-A1 Substituted piperazine compounds GILEAD PALO ALTO, INC. 2001-11-22 US disclosed
WO-2001062749-A1 SUBSTITUTED PIPERAZINE COMPOUNDS CV THERAPEUTICS, INC. (US) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010044541-A1 Substituted piperazine compounds ATP2A1, CPT1B, TNNC1 CYP3A4 3071/4885CYP2D6 1706/4885ADRB1 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.